FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHII
--

OMB APF	PROVAL
OMB Number:	3235-0287
Estimated average	burden
hours per response	. 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Ferson				2. Issuer Name and Ticker or Trading Symbol						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
<u>FOUSE JACQUALYN A</u>									X	V Director			10% Ow	ner	
(F	irst)	(Middle)		1010	J					<u> </u>	Officer ( below)	give title		Other (s below)	pecify
(Last) (First) (Middle) C/O AGIOS PHARMACEUTICALS, INC.						Trans	saction (Montl	h/Day/Year)			Ch	ief Execu	utive	Officer	
88 SIDNEY STREET					04/00/2022										
						4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Individual or Joint/Group Filing (Check Applicable				
IDGE M	ΙA	02139								- 1 '	Form fil	,		Ü	- 1
(S	tate)	(Zip)									Person	ed by More	ulan	One Report	ang
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Date				Execution Date, if any		Transaction Disposed Of (D) (Instr. 3, 4 Code (Instr.				) Securities Beneficia Owned Fo	Form (D) or ollowing (I) (In		Direct I Indirect I tr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
						Code V	Amount	(A) or (D)	r Price	Transacti	on(s)			msu. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
			ction   Derivative   Expiration Date   of Securities   (Month/Day/Year)   Underly   Derivati			of Securiti Underlying Derivative	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	(Instr. 4)				
\$29.46	04/08/2022		A		170,000		(1)	04/08/2032	Common stock	170,000	\$0	170,00	0	D	
(2)	04/08/2022		A		47,800		(3)	(3)	Common stock	47,800	\$0	47,800	0	D	
	(FOS PHARIET STREE IDGE M (SECURITY (Inst	(First) OS PHARMACEUTICALS EY STREET  IDGE MA  (State)  Ta Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security  \$29.46  04/08/2022  (2)  04/08/2022	(First) (Middle) OS PHARMACEUTICALS, INC. EY STREET  IDGE MA 02139  (State) (Zip)  Table I - Non-E Security (Instr. 3)  Table II - De (e.  2. Conversion or Exercise Price of Derivative Security  \$29.46 04/08/2022  (2) 04/08/2022	(First) (Middle) OS PHARMACEUTICALS, INC. EY STREET  IDGE MA 02139  (State) (Zip)  Table I - Non-Derivate (Month/Day)  Table II - Derivative (e.g., put Execution Date (Month/Day)/Year)  Price of Derivative Security  3. Transaction Date (Month/Day/Year) (Month/Day/Year)  (Code \$29.46 04/08/2022 A	AGIO  (First) (Middle)  OS PHARMACEUTICALS, INC.  EY STREET  IDGE MA 02139  (State) (Zip)  Table I - Non-Derivative Security (Instr. 3)  Table II - Derivative Security (Month/Day/Year)  Table II - Derivative Security (Month/Day/Year)  Table II - Derivative Security (Month/Day/Year)  (Month/Day/Year)  Tode (Instr. 8)  Code (Instr. 8)  Code V  \$29.46 04/08/2022 A	(First) (Middle) OS PHARMACEUTICALS, INC. EY STREET  IDGE MA 02139  (State) (Zip)  Table I - Non-Derivative Securities (Month/Day/Year)  Table II - Derivative Securities (e.g., puts, calls, warr (Month/Day/Year)  Conversion or Exercise Price of Derivative Security  Security  Security  3. Transaction Date (Month/Day/Year) (Month/Day/Year)  Table III - Derivative Securities (e.g., puts, calls, warr (Month/Day/Year)  Code (Instr. 8)  Code (Instr. 8)  Code (V (A)  \$29.46 04/08/2022 A 170,000  (2) 04/08/2022 A 47,800	AGIOS PHARM AGIO ]  (First) (Middle)  OS PHARMACEUTICALS, INC.  EY STREET  Table I - Non-Derivative Securities Action Date (Month/Day/Year)  Fecurity (Instr. 3)  Table II - Derivative Securities Acq (e.g., puts, calls, warrants of Execution Date if any (Month/Day/Year)  Table II - Derivative Securities Acq (e.g., puts, calls, warrants of Execution Date if any (Month/Day/Year)  Conversion or Exercise Price of Derivative Securities Acq (Month/Day/Year)  Security  Table II - Derivative Securities Acq (e.g., puts, calls, warrants of Execution Date, if any (Month/Day/Year)  Code (Instr. 8)  Code (Instr. 8)	AGIOS PHARMACEUT  (First) (Middle)  OS PHARMACEUTICALS, INC.  EY STREET  IDGE MA 02139  (State) (Zip)  Table I - Non-Derivative Securities Acquired, D  iecurity (Instr. 3)  2. Transaction Date (Month/Day/Year) (Month/Day/Year)  Fice of Derivative Securities Acquired, Discouling (e.g., puts, calls, warrants, options, (Month/Day/Year) (Month/Day/Year)  2. Code (Instr. 3)  Table II - Derivative Securities Acquired, Discouling (e.g., puts, calls, warrants, options, (Month/Day/Year) (Month/Day/Year)  Code (Instr. 3)  Table II - Derivative Securities Acquired, Discouling (e.g., puts, calls, warrants, options, (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)  Code (Instr. 8)  S. Number of Expiration D Code (Instr. 8)  Code (Instr. 3), 4 and 5)  Code (Instr. 3)  Date Exercisable  \$29.46 04/08/2022 A 170,000 (1)	AGIOS PHARMACEUTICALS, AGIO ]  (First) (Middle) OS PHARMACEUTICALS, INC.  EY STREET  Table I - Non-Derivative Securities Acquired, Disposed of (Month/Day/Year)  (State) (Zip)  Table II - Derivative Securities Acquired, Disposed of (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of (e.g., puts, calls, warrants, options, converties (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of (e.g., puts, calls, warrants, options, converties (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of (e.g., puts, calls, warrants, options, converties (Month/Day/Year)  Code (Instr. 8)  Security  Table II - Derivative Securities Acquired, Disposed of (e.g., puts, calls, warrants, options, converties (Month/Day/Year)  Code (Instr. 8)  Code (Instr. 8)  Code (Instr. 8)  Transaction (Month/Day/Year)  Code (Instr. 8)  Code (Instr. 8)  Code (Instr. 8)  Transaction (Month/Day/Year)  Code (Instr. 8)  Code (Instr. 8)  Code (Instr. 9)  Code (Instr	(First) (Middle) OS PHARMACEUTICALS, INC.  EY STREET  Table I - Non-Derivative Securities Acquired, Disposed of, or Be (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. fi any (Month/Day/Year))  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. fi any (Month/Day/Year))  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. fi any (Month/Day/Year))  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. fi any (Month/Day/Year))  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. fi any (Month/Day/Year))  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. fi any (Month/Day/Year))  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. fi any (Month/Day/Year))  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. fi any (Month/Day/Year))  Code   V   Amount   (A) o (D)   Exercisable and Securities Acquired (A) or (D) (Instr. fi any (Month/Day/Year))  Code   V   (A)   (D)   Date Exercisable and Securities Acquired (A) or (Instr. fi any (Month/Day/Year))  Security   Securities Acquired (A) or (D)   Date Exercisable and Securities Acquired (A) or (D) (Instr. fi any (Month/Day/Year))  Code   V   (A)   (D)   Date Exercisable Expiration Date (Instr. fi the Expiration Date (Instr. fi the Expiration Date) (Instr. fi the Expiration	AGIOS PHARMACEUTICALS, INC. [Che   AGIO ]  3. Date of Earliest Transaction (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)  4. If Amendment, Date of Original Filed (Month/Day/Year) (Month/Day/Year)  5. Date of Earliest Transaction (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)  6. Inc. Line (Month/Day/Year) (Month/Day/Ye	AGIOS PHARMACEUTICALS, INC.  (First) (Middle) OS PHARMACEUTICALS, INC.  EY STREET  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Execution Date (Month/Day/Year)  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of (Disposed of (Dispose	AGIOS PHARMACEUTICALS, INC.  (First) (Middle) OS PHARMACEUTICALS, INC.  EY STREET   AGIO ]  3. Date of Earliest Transaction (Month/Day/Year) (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Execution Date (Month/Day/Year)  (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of (Instr. 8)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Execution Date, flary (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Following Reported Transaction (Bonth/Day/Year)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (Instr. 3)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (Instr. 3)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (Instr. 3)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (Instr. 3)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (Instr. 3)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (Instr. 3)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (Instr. 3)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (Instr. 3)  Table II - Derivative Securities Derivative Securities (Instr. 5)  Table II - Derivative Securities Derivative Securities (Instr. 5)  Table II - Derivative Security (Instr. 3)  Table II - Derivative Securities Derivative Securities Derivative Security (Instr. 3)  Table II - Derivative Securities Derivative Securities Derivative Security (Instr. 5)  Table II - Derivative Security (Instr. 5)  Table II - Non-Derivative Securities Derivative Security (Instr. 5)  Table II - Non-Derivative Securities Derivative Security (Instr. 5)  Table II - Non-Derivative Securities Der	AGIOS PHARMACEUTICALS, INC. [Check all applicable)  (First) (Middle) OS PHARMACEUTICALS, INC. [AGIO]  3. Date of Earliest Transaction (Month/Day/Year)  (State)  (State)  (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Execution Date (Month/Day/Year)  (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Following (Poprivative Securities)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Following (Poprivative Securities)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Following (Poprivative Securities)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Following (Poprivative Securities)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Following (Poprivative Securities)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Following (Poprivative Securities)  Table II - Derivative Securities Acquired (Disposed of, or Beneficially Owned Following (Poprivative Securities)  Table II - Derivative Securities Acquired (Disposed of, or Beneficially Owned (Pol) (Instr. 3 and 4)  Table II - Derivative Securities Acquired (Disposed of, or Beneficially Owned (Pol) (Instr. 3 and 4)  Table II - Derivative Securities Acquired (Disposed of, or Beneficially Owned (Pol) (Instr. 3 and 4)  Table II - Derivative Securities Acquired (Disposed of, or Beneficially Owned (Pol) (Instr. 3 and 4)  Table II - Derivative Securities Acquired (A) (Pol) (Instr. 3 and 4)  Table II - Derivative Securities Acquired (A) (Pol) (Instr. 3 and 4)  Table II - Derivative Securities Acquired (A) (Pol) (Pol) (Instr. 3 and 4)  Table II - Derivative Securities Acquired (A) (Pol)	AGIOS PHARMACEUTICALS, INC.  (First) (Middle) OS PHARMACEUTICALS, INC.  EY STREET    AGIO

- 1. This option was granted on April 8, 2022. The shares underlying this option vest as to 25% of the underlying shares on April 8, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.
- 2. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock
- 3. The restricted stock units were granted on April 8, 2022. Beginning on April 8, 2023, the shares underlying the restricted stock units will vest in three equal annual installments.

## Remarks:

/s/ William Cook, as Attorneyin-fact for Jacqualyn Fouse

04/12/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.